Chromatin/Epigenetics
Epigenetics is the heritable modifications in gene expression that is not associated with changes in DNA sequence. Epigenetic modifications occur mostly on DNA or on the histone octamer. There are several types of epigenetics modifications, DNA methylation by DNA-methyl transferase (DNMT) and covalent modification of histones (e.g. acetylation, methylation, phosphorylation and ubiquitination). Histone acetylation by histone acetyltransferases (HATs) is involved in transcriptional activation, whereas histone deacetylation by histone deacetylases (HDACs) is connected with transcriptional repression. Histone demethylation is associated with lysine-specific demethylase (LSD) and JmjC domain containing histone demethylase (JHDM).
The nucleosome is consisted of four histone proteins (H2A, H2B, H3, and H4), they are primary building block of chromatin. The addition and removal of specific chemical groups refers to as epigenetic marks, it regulates chromatin structure and affects gene expression. Moreover, RNA is intimately involved in the formation of a repressive chromatin state.
Epigenetic mechanism responds to environmental changes at the cellular level and thus influences cellular plasticity. Chromatin and epigenetic regulation play a significant role in the programming of the genome during development and stress response, defects in epigenetics can lead to cancer, inflammation and metabolic disorders etc.
- A4490 I-CBP 112Target: CREBBP|EP300Summary: CBP/EP300 bromodomain inhibitor
- A4491 SGC-CBP302 CitationTarget: CREBBP|EP300Summary: Inhibitor of CREBBP/EP300 bromodomain,potent
- A8810 UNC669Summary: L3MBTL antagonist,potent and selective
- B1499 RVX-2082 CitationSummary: Potent BET bromodomain inhibitor
- B1498 I-BET-7624 CitationTarget: BromodomainsSummary: BET inhibitor,highly potent
- B1500 I-BET151 (GSK1210151A)2 CitationTarget: Bromodomain and Extra-Terminal motif (BET)Summary: Selective BET inhibitor
- B5670 I-BET 151 hydrochloride1 CitationSummary: BET bromodomain inhibitor
- B4895 OF-1Summary: BRPF1B and BRPF2 bromodomain inhibitor
- B4915 BAZ2-ICRSummary: Selective BAZ2 bromodomain inhibitor
- B4916 GSK 5959Summary: BRPF1 bromodomain inhibitor